Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  stage IIIA breast cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 223 for your search:
Start Over
Aromatase Inhibitor Clinical Trial
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 40 to 70
Sponsor: NIGMS
Protocol IDs: 0412-14, UO1-GM61373-06, NCT00228956
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO# 08-1373, NCT00900744
Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-09-14B, NCT00984269
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P0334, NCT01501487
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: A11-3691, NCT01537029
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000513169, WHC-MRI-GU-2006-097, NCT00397761
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MM-302-02-02-03, NCT02213744
Regional Anesthesia and Breast Cancer Recurrence
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 06-692, NCT00418457
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 102-00-301, NCT01204801
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02623, CDR0000692475, SWOG-S1007, S1007, U10CA180888, U10CA032102, NCT01272037
Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A221102, CDR0000730083, NCI-2012-00719, U10CA037447, CALGB-A221102, NCCTG-N10C7, NCT01573442
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CBKM120F2303, 2012-002571-34, NCT01633060
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S1207, U10CA032102, NCI-2012-01995, SWOG-S1207, NCT01674140
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG78/BIG 1-13/NSABP-B-54-I, 2013-001040-62, NCT01864746
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NSABP-B-51/RTOG-1304, NCI-2012-03198, U10CA012027, NCT01872975
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A011202, U10CA031946, NCI-2013-00875, NCT01901094
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 673-301, U1111-1155-7579, NCT01945775
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A011106, NCI-2013-01340, U10CA031946, NCT01953588
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-02228, NSABP B-52, U10CA012027, U10CA180868, NCT02003209
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D081CC00006, BIG 6-13, NSABP B-55, NCT02032823
A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO28408, NCT02131064
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-914, 2014-000345-70, NCT02163694
A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 an over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B3271004, REFLECTIONS B327-04, 2013-004679-11, NCT02187744
Start Over